GlassScriptPhysician profile
April Wiseman
NPI 1205470747
$5,671.65
in general payments reported to CMS, 2019-2025
27 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $924 · 2023: $1,324 · 2024: $1,682 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,127 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.83 |
| Education | $403.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,459.00 | 2021-2025 | Ilumya |
| Abbvie INC. | $1,320.68 | 2021-2025 | |
| Genzyme Corporation | $586.95 | 2022-2025 | |
| Amgen INC. | $285.84 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $282.29 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $252.94 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $238.85 | 2022-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $199.98 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $167.10 | 2022-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $123.23 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $102.13 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $100.26 | 2025 | |
| Incyte Corporation | $89.46 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $69.30 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $64.13 | 2023-2025 | Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $45.79 | 2024-2025 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $45.35 | 2024-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $40.87 | 2023-2024 | |
| Dermavant Sciences, INC. | $39.47 | 2023 | Vtama |
| Botanix Sb INC | $28.91 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $26.88 | 2023 | Idacio |
| Dermira, INC. | $25.76 | 2021 | |
| Epi Health, LLC | $17.69 | 2022 | |
| Smith+Nephew, INC. | $16.29 | 2025 | Grafix Pl |
| Sebela Pharmaceuticals INC. | $15.98 | 2021 | |
| Journey Medical Corporation | $13.59 | 2022 | |
| Almirall LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Wiseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.